Please ensure Javascript is enabled for purposes of website accessibility
Amar Khatri

Amar Khatri


Recent articles


Is CRISPR Therapeutics Stock a Buy?

The gene-editing pioneer is a favorite among biotech investors and its stock is hitting new highs.


2 Top Cancer Treatment Stocks To Watch In July

These hidden gems have the potential to deliver significant returns to their shareholders over the long run.


These 2 Pharma Stocks Could Be Top Stocks in 2020

These pharma stocks are undervalued, and could be solid picks over the long term.


Is Dynavax Technologies Stock a Buy?

This stock has the potential to break new highs with its key hepatitis B vaccine and emerging vaccine-adjuvant platform for COVID-19 vaccines.


2 Biotech Stocks That Could Soar in 2020

These companies offer promising pipelines that could deliver in the long term.


Better Buy: Illumina vs. Guardant Health

Which stock wins in a matchup between these two healthcare stocks?


2 Top Cancer Treatment Stocks to Buy in June

If you have cash to spare, these cancer stocks are set to soar.


3 Drug Stocks That Could Soar in 2020

Have extra cash to spare? These drug stocks are significantly undervalued and could make you wealthy in the long run.


Is Aurinia Pharmaceuticals Stock a Buy?

This biopharma’s drug could be a home run for investors.


Better Buy: CRISPR Therapeutics vs. Intellia

Which gene editing stock wins this matchup?


Is Acadia Pharmaceuticals a Buy?

A strong Q1 performance set the tone, but commitment to its strategy will be key to drive the stock higher.


Is Amarin Stock a Buy?

Record revenues, international growth, and a potential legal strategy may provide upside.

DNA sequence genetics test genomics

Is Exact Sciences Stock a Buy?

Q1 results were mixed, but the company’s strategy may be key for top-line growth ahead.


Is Catalyst Pharmaceuticals a Buy?

Several catalysts could drive this biopharma higher, but there are some significant risks ahead, too.

Blue poker chips on stock market background

Your 2 Top Profit Opportunities in 2020

These two underrated biotech stocks have the potential to soar.

financial health stethoscope money cash hundred bills medical healthcare

Is Exelixis a Buy?

Cheap and ready to outperform, this under-the-radar biotech stock could be a winner.

red blood cells abstract

Is BioMarin Pharmaceutical Stock a Buy?

Is this a prime opportunity for investors to buy the gene therapy drugmaker?

bottles of prescription medicine sitting on shelves in cabinet drugs pills

This 1 Stock Is a Good Buy During the Coronavirus Sell-Off

Acadia Pharmaceuticals' track record of success and strong pipeline offers an attractive long-term opportunity for investors, especially at a depressed price.

hypodermic needles syringe drug pharma

Can Halozyme Therapeutics Continue Its Momentum in 2020?

The biopharma's strategic moves in 2019 may set the company up for long term growth.

research scientists drugs pharma biotech

Here's Why Clovis Oncology Has Upside Potential in 2020

The cancer-drug maker has a novel medicine that may provide growth opportunities in other areas of cancer.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.